AR101637A1 - Combinaciones de gabapentinoides y ligandos de receptores sigma - Google Patents
Combinaciones de gabapentinoides y ligandos de receptores sigmaInfo
- Publication number
- AR101637A1 AR101637A1 ARP140104701A ARP140104701A AR101637A1 AR 101637 A1 AR101637 A1 AR 101637A1 AR P140104701 A ARP140104701 A AR P140104701A AR P140104701 A ARP140104701 A AR P140104701A AR 101637 A1 AR101637 A1 AR 101637A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- aromatic
- nr8r9
- heterocyclyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 108010085082 sigma receptors Proteins 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 17
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 239000011885 synergistic combination Substances 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 208000002193 Pain Diseases 0.000 abstract 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- -1 ethyl hydrochloride Chemical compound 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382517 | 2013-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101637A1 true AR101637A1 (es) | 2017-01-04 |
Family
ID=49876521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104701A AR101637A1 (es) | 2013-12-17 | 2014-12-17 | Combinaciones de gabapentinoides y ligandos de receptores sigma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160310501A1 (enExample) |
| EP (1) | EP3082790A1 (enExample) |
| JP (1) | JP2017503765A (enExample) |
| KR (1) | KR20160098426A (enExample) |
| CN (1) | CN105873580B (enExample) |
| AR (1) | AR101637A1 (enExample) |
| AU (1) | AU2014364644A1 (enExample) |
| CA (1) | CA2933057A1 (enExample) |
| IL (1) | IL245977A0 (enExample) |
| MA (1) | MA39146A1 (enExample) |
| MX (1) | MX2016007286A (enExample) |
| PH (1) | PH12016501095A1 (enExample) |
| SG (1) | SG11201604478UA (enExample) |
| TN (1) | TN2016000229A1 (enExample) |
| TW (1) | TW201607539A (enExample) |
| WO (1) | WO2015091505A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| AU2018390563B2 (en) * | 2017-12-19 | 2024-07-04 | University Of Tennessee Research Foundation | W/o/w microemulsions for ocular administration |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN120437109B (zh) * | 2025-07-09 | 2025-09-26 | 湖南一格制药有限公司 | 一种稳定性优异的苯磺酸美洛加巴林制剂组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| AU677008B2 (en) | 1992-05-20 | 1997-04-10 | Northwestern University | Gaba and L-glutamic acid analogs for antiseizure treatment |
| BR9813284B1 (pt) | 1997-10-27 | 2012-08-21 | aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica. | |
| CN1210268C (zh) | 1997-12-16 | 2005-07-13 | 沃尼尔·朗伯公司 | ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途 |
| CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| TR200001795T2 (tr) | 1997-12-16 | 2000-11-21 | Warner-Lambert Company | 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı. |
| EP1082306A1 (en) | 1998-05-26 | 2001-03-14 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
| US6166072A (en) | 1998-08-03 | 2000-12-26 | Allelix Neuroscience, Inc. | Amino acid derivatives |
| AU1602100A (en) | 1998-11-25 | 2000-06-13 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| JP2002538221A (ja) * | 1999-03-10 | 2002-11-12 | ワーナー−ランバート・カンパニー | 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法 |
| EP1180094B1 (en) | 1999-05-26 | 2004-07-28 | Warner-Lambert Company | Fused polycyclic amino acids as pharmaceutical agents |
| AU4673200A (en) | 1999-05-28 | 2000-12-18 | Warner-Lambert Company | 3-heteroarylalkyl substituted gaba analogs |
| ES2185591T3 (es) | 1999-06-02 | 2003-05-01 | Warner Lambert Co | Amino hererociclos utiles como agentes farmaceuticos. |
| CA2444053C (en) | 2001-04-19 | 2008-06-17 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
| AU2005276590B2 (en) * | 2004-08-27 | 2011-05-19 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| EP1820502A1 (en) * | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2292236A1 (en) | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| HRP20161128T1 (hr) | 2009-11-25 | 2016-11-18 | Laboratorios Del Dr. Esteve, S.A. | Hidrokloridna sol 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolina |
| EP2335688A1 (en) | 2009-11-25 | 2011-06-22 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions comprising sigma receptor ligands |
| PL2531177T3 (pl) | 2010-02-04 | 2016-11-30 | Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1h-pirazol-3-ilo]oksy]etylo]morfoliny i solwaty | |
| EP2353591A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) * | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2460519A1 (en) | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
| EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2818166A1 (en) * | 2013-06-26 | 2014-12-31 | Laboratorios del Dr. Esteve S.A. | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
-
2014
- 2014-12-16 SG SG11201604478UA patent/SG11201604478UA/en unknown
- 2014-12-16 TW TW103143904A patent/TW201607539A/zh unknown
- 2014-12-16 AU AU2014364644A patent/AU2014364644A1/en not_active Abandoned
- 2014-12-16 JP JP2016536584A patent/JP2017503765A/ja not_active Ceased
- 2014-12-16 WO PCT/EP2014/077992 patent/WO2015091505A1/en not_active Ceased
- 2014-12-16 MX MX2016007286A patent/MX2016007286A/es unknown
- 2014-12-16 MA MA39146A patent/MA39146A1/fr unknown
- 2014-12-16 TN TN2016000229A patent/TN2016000229A1/en unknown
- 2014-12-16 CN CN201480072218.6A patent/CN105873580B/zh not_active Expired - Fee Related
- 2014-12-16 EP EP14823952.8A patent/EP3082790A1/en not_active Withdrawn
- 2014-12-16 KR KR1020167018971A patent/KR20160098426A/ko not_active Withdrawn
- 2014-12-16 US US15/104,752 patent/US20160310501A1/en not_active Abandoned
- 2014-12-16 CA CA2933057A patent/CA2933057A1/en not_active Abandoned
- 2014-12-17 AR ARP140104701A patent/AR101637A1/es unknown
-
2016
- 2016-06-01 IL IL245977A patent/IL245977A0/en unknown
- 2016-06-08 PH PH12016501095A patent/PH12016501095A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105873580A (zh) | 2016-08-17 |
| WO2015091505A1 (en) | 2015-06-25 |
| MX2016007286A (es) | 2016-08-04 |
| JP2017503765A (ja) | 2017-02-02 |
| TN2016000229A1 (en) | 2017-10-06 |
| TW201607539A (zh) | 2016-03-01 |
| CA2933057A1 (en) | 2015-06-25 |
| SG11201604478UA (en) | 2016-07-28 |
| AU2014364644A1 (en) | 2016-06-23 |
| US20160310501A1 (en) | 2016-10-27 |
| EP3082790A1 (en) | 2016-10-26 |
| KR20160098426A (ko) | 2016-08-18 |
| MA39146A1 (fr) | 2017-11-30 |
| IL245977A0 (en) | 2016-07-31 |
| CN105873580B (zh) | 2020-08-25 |
| PH12016501095A1 (en) | 2016-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101637A1 (es) | Combinaciones de gabapentinoides y ligandos de receptores sigma | |
| AR101638A1 (es) | Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma | |
| AR096709A1 (es) | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
| AR084730A1 (es) | Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos | |
| AR100021A1 (es) | Combinaciones de ligando de receptores sigma y aine | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR107694A1 (es) | Heteroarilos inhibidores de pad4 | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
| SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| TN2014000436A1 (en) | Inhibitors of platelet aggregation | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| AR082441A1 (es) | Uso de ligandos sigma en la hiperalgesia inducida por opioides | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR086632A1 (es) | Ligandos sigma para la prevencion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CO6410301A2 (es) | 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos | |
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| MX2016014197A (es) | 4-fenilpiperidinas sustituidas, su preparacion y uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |